PharmiNews

The Directory of Pharma Companies and News

BMS

Category: Pharmaco
Category: Pharmaco

BMS News

DateNews
2017-01-06Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration
2017-01-05Bristol-Myers Squibb Announces Immunotherapy Clinical Collaboration with Janssen to Evaluate Opdivo (nivolumab) in Combi...
2016-12-29Bristol-Myers Squibb to Take Part at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top
2016-12-21Giovanni Caforio Named Chairman of Bristol-Myers Squibb’s Board of Directors
2016-12-21Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combina...
2016-12-20Bristol-Myers Squibb Signs Exclusive Worldwide License Agreement with PsiOxus Therapeutics for NG-348, an “Armed” Oncoly...
2016-12-13Bristol-Myers Squibb Strengthens Capabilities with Evolution of its U.S. Geographic Footprint
2016-12-09Bristol-Myers Squibb to Announce Results for Fourth Quarter 2016 on January 26, 2017
2016-12-06Opdivo (nivolumab) Alone or Combined With Yervoy (ipilimumab) Shows Encouraging Response and Survival Rates in Recurrent...
2016-12-06Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Ve...
2016-12-05Encouraging Survival Observed With Opdivo (nivolumab) Plus Yervoy (ipilimumab) With Longer Follow-up in First-line Advan...
2016-11-30Bristol-Myers Squibb to Take Part at the Citi 2016 Global Healthcare Conference
2016-11-22European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed...
2016-11-16Bristol-Myers Squibb Presents New Data at IASLC 17th World Conference on Lung Cancer Underscoring Progress and Leadershi...
2016-11-16Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Drug ...
2016-09-27Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opd...
2016-09-22Bristol-Myers Squibb to Take Part in Leerink Partners Immuno-Oncology Roundtable Conference
2016-09-20European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Advan...
2016-09-20Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio
2016-09-12Bristol-Myers Squibb’s Response to ICER’s Call for Improvements to its Value Assessment Framework
2016-09-07Bristol-Myers Squibb to Announce Results for Third Quarter 2016 on October 27
2016-09-07Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
2016-09-07Bristol-Myers Squibb Employees Cycle Coast to Coast to Raise Money and Awareness for Cancer Research
2016-09-06European Commission Approves Bristol-Myers Squibb’s ORENCIA® (abatacept) for the Treatment of Highly Active and Progress...
2016-08-31Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ESMO 2016 Congress Highlights
2016-08-23Bristol-Myers Squibb and Pfizer to Present New Eliquis (apixaban) Analyses at ESC Congress 2016
2016-08-05Bristol-Myers Squibb Statement on Top-Line Results from CheckMate -026
2016-08-05Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-...
2016-07-26Bristol-Myers Squibb Announces New Research Collaboration with Janssen in Immuno-Oncology Focused on Lung Cancer
2016-07-25Bristol-Myers Squibb Appoints Fouad Namouni, M.D., Oncology Development Head
2016-07-25AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdi...
2016-07-25CHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult...
2016-07-20Bristol-Myers Squibb Announces Availability of FDA-Approved ORENCIA® (abatacept) ClickJect™, a Self-Administered Subcuta...
2016-07-18Bristol-Myers Squibb Announces Regulatory Updates for Opdivo (nivolumab) in Previously Treated Recurrent or Metastatic S...
2016-07-05Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
2016-06-30Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combinatio...
2016-06-29Bristol-Myers Squibb’s Response to ICER’s Draft Scoping Document “Treatment Options for Advanced Non-Small-Cell Lung Can...
2016-06-24Sickle Cell Partnership Creates Demonstration Project to Treat Children in Angola
2016-06-20Murdo Gordon Appointed Executive Vice President and Chief Commercial Officer
2016-06-10New Data on Bristol-Myers Squibb’s Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma...
2016-06-09Bristol-Myers Squibb to Announce Results for Second Quarter 2016 on July 28
2016-06-09Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Acr...
2016-06-08Bristol-Myers Squibb Announces New Rheumatoid Arthritis Research and Real-World Data at the Annual European Congress of ...
2016-06-07Bristol-Myers Squibb and MD Anderson Announce New Research Collaboration in Immuno-Oncology Focused on Lung Cancer
2016-06-06Long-Term Data from Two Trials Evaluating the Opdivo® (nivolumab) and Yervoy® (ipilimumab) Regimen in Advanced Melanoma ...
2016-06-05Long-Term Survival and Improvement in Quality of Life Observed with Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma...
2016-06-05First Presentation of Phase 2 CheckMate -142 Study Evaluating Opdivo® (nivolumab) Alone or in Combination with Yervoy® (...
2016-06-05Promising Response Rates with Opdivo® (nivolumab) Observed in Advanced Form of Bladder Cancer from Phase 1/2 Study Check...
2016-06-04Opdivo® (nivolumab) and Yervoy® (ipilimumab) Combination Regimen Shows Clinically Meaningful Responses in First-Line Adv...
2016-05-31Bristol-Myers Squibb to Take Part in Goldman Sachs 37th Annual Global Health Care Conference
2016-05-26How to Define Value: Patient Outcomes or Modeling?
2016-05-18Breadth and Depth of Bristol-Myers Squibb’s Immuno-Oncology Clinical Development Program to be Showcased at 2016 America...
2016-05-18Two-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained Benefit In Patients wit...
2016-05-17Bristol-Myers Squibb Opens Expanded Biologics Facility
2016-05-17Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymp...
2016-05-11European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo® (nivolumab) ...
2016-05-11Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab) for the Treatment of Mu...
2016-05-05Modern Family Star Eric Stonestreet and His Mom, a Two Time Cancer Survivor, Join Forces to Raise Awareness of Immuno-On...
2016-04-27Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference
2016-04-25Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administrat...
2016-04-19First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versu...
2016-04-17First Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Sh...
2016-04-14U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Supplemental Biologics License Appl...
2016-04-06European Commission Approves Bristol-Myers Squibb’s Opdivo® (nivolumab) for Previously Treated Advanced Renal Cell Carci...
2016-04-06European Commission Approves Expanded Use of Opdivo® (nivolumab) to Include Previously Treated Metastatic Non-Squamous N...
2016-04-01Bristol-Myers Squibb Completes Previously Announced Acquisition of Padlock Therapeutics, Inc.
2016-04-01Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) for...
2016-03-30Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) a...
2016-03-30European Medicines Agency Validates Bristol-Myers Squibb’s Application for Opdivo® (nivolumab) for the Treatment of Clas...
2016-03-24Bristol-Myers Squibb to Present at William Blair Conference, Cancer Immunotherapy: A Long-Awaited Reality
2016-03-23Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.
2016-03-16Bristol-Myers Squibb to Present New Overall Survival Data for Opdivo® (nivolumab) as Monotherapy and in Combination with...
2016-03-15Bristol-Myers Squibb to Announce Results for First Quarter 2016 on April 28
2016-03-09Bristol-Myers Squibb to Present at Barclays Global Health Care Conference
2016-03-07Bristol-Myers Squibb and LabCentral Team Up in Cambridge, Massachusetts to Support Promising Biotech Startup Companies
2016-03-03Bristol-Myers Squibb Names Peter J. Arduini to Board of Directors
2016-02-26Bristol-Myers Squibb Receives Two Positive CHMP Opinions for Opdivo® (nivolumab) for Patients with Previously Treated Ad...
2016-02-22Data Presented at APASL from First Completed Phase 3 Trial of All-oral Chronic Hepatitis C Regimen in Chinese Patient Po...
2016-02-22Bristol-Myers Squibb Completes Previously Announced Sale of its HIV R&D Portfolio to ViiV Healthcare
2016-02-16Bristol-Myers Squibb and Dana-Farber Cancer Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncolo...
2016-02-05U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Pati...
2016-02-03Bristol-Myers Squibb to Take Part in Leerink Swann Global Healthcare Conference
2016-02-01Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin Cancer Screening, Care ...
2016-02-01Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigati...
2016-01-29Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion for Investigational Antibody, Empliciti (elotuzumab), for ...
2016-01-28Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results
2016-01-28CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early
2016-01-28European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patient...
2016-01-23Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable o...
2016-01-05Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
2015-12-23Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedo...
2015-12-18Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare
2015-12-17BMS and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Re...
2015-12-14Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malig...
2015-12-11Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2015 on January 28
2015-12-10AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Majo...
2015-12-08Bristol-Myers Squibb Completes Previously Announced Acquisition of Cardioxyl Pharmaceuticals, Inc.
2015-12-08Bristol-Myers Squibb Establishes Center for Molecular Synthesis in New Collaboration with Princeton University
2015-12-08Bristol-Myers Squibb Announces Dividend Increase
2015-12-05New Longer-Term Data for Empliciti (elotuzumab) Showed a Continued Progression-Free Survival Benefit in Patients with Re...
2015-12-04Bristol-Myers Squibb Receives Multiple Myeloma Research Foundation’s 2015 Collaborator Award
2015-12-01Bristol-Myers Squibb Foundation Marks World AIDS Day with Grants Totaling More than $3.5M for HIV and Cervical and Breas...
2015-11-30Bristol-Myers Squibb to Present New Data across Multiple Blood Cancers at the 57th Annual Meeting & Exposition of the Am...
2015-11-30Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multi...
2015-11-27Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma
2015-11-24Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Sur...
2015-11-24European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo® European Marketing Authorizat...
2015-11-24Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for t...
2015-11-18New Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced ...
2015-11-16Data from ALLY-3+ Trial Investigating Daklinza (daclatasvir) in Combination with Sofosbuvir and Ribavirin in Chronic Hep...
2015-11-16U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo ...
2015-11-12Bristol-Myers Squibb to Present New Data for Opdivo (nivolumab) in Advanced Melanoma, as Monotherapy and in Combination ...
2015-11-11Bristol-Myers Squibb Foundation Awards Five Grants Totaling More than $2.77M to Programs Supporting Post-9/11 Military V...
2015-11-06Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the American Heart Association (AHA) Scient...
2015-11-05Bristol-Myers Squibb to Present Data from 24 Abstracts in Immunoscience at the American College of Rheumatology (ACR) 20...
2015-11-05European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Previ...
2015-11-03Bristol-Myers Squibb and the Johns Hopkins Kimmel Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Imm...
2015-11-03Bristol-Myers Squibb to Present at Credit Suisse 2015 Health Care Conference
2015-11-02Bristol-Myers Squibb to Acquire Cardioxyl Pharmaceuticals, Inc.
2015-10-28Bristol-Myers Squibb’s Opdivo (nivolumab) Recipient of Prix Galien USA 2015 Award for Best Biotechnology Product
2015-10-28Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for Yervoy (ipilimumab) as Adjuvant Tr...
2015-10-27Bristol-Myers Squibb Reports Third Quarter Financial Results
2015-10-23Complete Phase 2a Study of HIV-1 Investigational Maturation Inhibitor Demonstrates Positive Results for Therapy Designed...
2015-10-21Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD
2015-10-15Bristol-Myers Squibb Enters into Exclusive Worldwide License and Collaboration Agreement with Five Prime Therapeutics fo...
2015-10-15Bristol-Myers Squibb Appoints Paul Biondi Senior Vice President, Head of Business Development
2015-10-15NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients with Chronic Hepatitis C Genotypes 1, 3 and 4
2015-10-13Bristol-Myers Squibb's Ready. Raise. Rise.™ Recognizes 23 Cancer Advocacy Groups in Immuno-Oncology Research Awareness C...
2015-10-09Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell...
2015-10-06U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs
2015-10-01Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (i...
2015-09-28REPEAT/Actor Jack Huston Challenges Europeans to Take ACTion Against Lung Cancer
2015-09-28Bristol-Myers Squibb Launches Working Together for Patients, a Program Highlighting the Company’s Commitment to Patients
2015-09-27Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Ce...
2015-09-26Actor Jack Huston Challenges Europeans to Take ACTion Against Lung Cancer
2015-09-25Bristol-Myers Squibb and Moffitt Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare...
2015-09-25Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients wi...
2015-09-25Bristol-Myers Squibb Announces U.S. Food and Drug Administration Regulatory Filing Update for the Opdivo+Yervoy Regimen ...
2015-09-24Bristol-Myers Squibb to Take Part in Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
2015-09-22Bristol-Myers Squibb to Announce Results for Third Quarter 2015 on October 27
2015-09-18Bristol-Myers Squibb Foundation Awards Additional Grants to Promote Cervical Cancer Screenings and Services for Women Li...
2015-09-16Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administrati...
2015-09-10Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
2015-09-10Bristol-Myers Squibb Employees Cycle Nearly 2,900 Miles Across the Country to Raise Money for Cancer Research
2015-09-10Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Ge...
2015-09-09Bristol-Myers Squibb and Pfizer Enroll First Patient in Phase 4 AUGUSTUS Trial to Evaluate Safety of Eliquis (apixaban) ...
2015-09-07New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Adva...
2015-09-07Follow-up Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrates Sustained Survival Results in Patients with Previ...
2015-09-02U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previousl...
2015-09-02Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights
2015-09-01U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzuma...
2015-08-31Bristol-Myers Squibb Enters Agreement Providing Exclusive Right to Acquire Promedior, Inc. and its Novel PRM-151 in Deve...
2015-08-30Bristol-Myers Squibb and QIMR Berghofer Medical Research Institute Announce Worldwide Collaboration to Discover Novel Im...
2015-08-24Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015
2015-08-13FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Five-Year First-Line and Seven-Year Second...
2015-08-12U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolum...
2015-08-04Bristol-Myers Squibb and The Leukemia & Lymphoma Society Announce Charitable Donation to Support Critical Routine Testin...
2015-08-03Bristol-Myers Squibb Establishes Collaborative Immuno-Oncology Rare Population Malignancy (I-O RPM) Program in the U.S.
2015-07-29Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Op...
2015-07-27European Medicines Agency Validates and Grants Accelerated Assessment of Marketing Authorization Application for Emplici...
2015-07-24FDA Approves Daklinza (daclatasvir) for the Treatment of Patients with Chronic Hepatitis C Genotype 3
2015-07-23Bristol-Myers Squibb Reports Second Quarter Financial Results
2015-07-23European Medicines Agency Validates Two Parallel Type II Variation Applications to Extend the Opdivo (nivolumab) Indicat...
2015-07-21Bristol-Myers Squibb Receives U.S. FDA Breakthrough Therapy Designation for Investigational HIV-1 Attachment Inhibitor f...
2015-07-21Second-Generation Investigational HIV-1 Maturation Inhibitor Demonstrates Positive New Phase IIa Results, Supporting Con...
2015-07-20CheckMate -025, a Pivotal Phase III Opdivo (nivolumab) Renal Cell Cancer Trial, Stopped Early
2015-07-20European Commission Approves Nivolumab BMS, the First PD-1 Immune Checkpoint Inhibitor in Europe Proven to Extend Surviv...
2015-07-16European Commission Approves Bristol-Myers Squibb’s Evotaz (atazanavir and cobicistat fixed-dose combination) for the Tr...
2015-07-15MUSC and Bristol-Myers Squibb Announce Translational Research Collaboration Focused on Fibrotic Diseases
2015-06-25Bristol-Myers Squibb Expands R&D Presence Within Hubs of World Class Science and Innovation
2015-06-22Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A™ Study Demonstrating t...
2015-06-19European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab), the First and Only PD-1 Checkpoint Inhibitor App...
2015-06-18Bristol-Myers Squibb to Announce Results for Second Quarter 2015 on July 23
2015-06-11Bristol-Myers Squibb Demonstrates Commitment to Hematology and Advancing Research and Development Across Multiple Blood ...
2015-06-09New Post Hoc Analyses of Phase 3b Data Examine Treatment with Orencia (abatacept) Plus Methotrexate (MTX) in Patients wi...
2015-06-03Bristol-Myers Squibb to Present Data from 14 Abstracts on Orencia (abatacept) at the European League Against Rheumatism ...
2015-06-02Bristol-Myers Squibb to Take Part in Goldman Sachs 36th Annual Global Health Care Conference
2015-06-02Adding Investigational Agent Elotuzumab to Standard Treatment for Multiple Myeloma Significantly Reduced the Risk of Dis...
2015-06-01U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo+Yervoy Regimen in Patien...
2015-05-31Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen or Opdivo Monoth...
2015-05-31Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamo...
2015-05-29Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Superior Overall Survival Versus Standard of Care (docetaxel) in ...
2015-05-29Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First to Demonstrat...
2015-05-28Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
2015-05-27Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer
2015-05-22Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the ...
2015-05-20Bristol-Myers Squibb Receives Amended U.S. FDA Breakthrough Therapy Designation for Investigational Daclatasvir-based He...
2015-05-19Eric Stonestreet, of Television’s Hit Comedy, “Modern Family” Joins Forces with Bristol-Myers Squibb to Launch Ready. Ra...
2015-05-13Bristol-Myers Squibb to Present Data at 2015 American Society of Clinical Oncology (ASCO) Annual Meeting that Demonstrat...
2015-05-12Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Up to $500 Million Aggregate Principal Amo...
2015-05-12Bristol-Myers Squibb Announces the Early Results of its Cash Tender Offer For Up to $400 Million Aggregate Principal Amo...
2015-05-06Long-Term, 7-Year Study of Nulojix® (belatacept) Regimen Demonstrates Statistically Significant Relative Risk Reduction ...
2015-05-04Bristol-Myers Squibb to Present at Bank of America Merrill Lynch 2015 Health Care Conference
2015-04-29Bristol-Myers Squibb to Take Part in Deutsche Bank Global Health Care Conference
2015-04-29Bristol-Myers Squibb Prices €1.15 Billion of Senior Notes
2015-04-29U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Patients ...
2015-04-28Bristol-Myers Squibb Announces Cash Tender Offer For Up to $400 Million Aggregate Principal Amount of its Outstanding De...
2015-04-28Bristol-Myers Squibb Reports First Quarter Financial Results
2015-04-25ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hep...
2015-04-24Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Ad...
2015-04-20First Randomized Study Evaluating Opdivo (nivolumab)+Yervoy (ipilimumab) Regimen Demonstrates Superior Efficacy Versus Y...
2015-04-17CheckMate -057, a Pivotal Phase III Opdivo (nivolumab) Lung Cancer Trial, Stopped Early
2015-04-16Lilly, Bristol-Myers Squibb Restructure Erbitux® (cetuximab) Collaboration in North America
2015-04-08Bristol-Myers Squibb Completes Previously Announced Acquisition of Flexus Biosciences, Inc.
2015-04-06Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascul...
2015-03-27Bristol-Myers Squibb to Announce Results for First Quarter 2015 on April 28
2015-03-24Bristol-Myers Squibb Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune...
2015-03-12Bristol-Myers Squibb Announces Acceptance of New Drug Application for Investigational Daclatasvir for FDA Review for the...
2015-03-04FDA Approves Opdivo (nivolumab) for the Treatment of Patients with Previously Treated Metastatic Squamous Non-Small Cell...
2015-03-04Bristol-Myers Squibb Announces U.S. FDA Approval of an Additional Indication for Opdivo (nivolumab)
2015-03-04Bristol-Myers Squibb Signs Exclusive Agreement with Bavarian Nordic for PROSTVAC®, a Prostate-Specific Antigen-Targeting...
2015-03-02Bristol-Myers Squibb Announces Dividend
2015-03-02U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Yervoy® (ipilimumab) as Adjuvan...
2015-02-27U.S. Food and Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for the Treatment of Ad...
2015-02-26Study of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replicati...
2015-02-26ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigation...
2015-02-2548-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation
2015-02-24Bristol-Myers Squibb to Present at Cowen and Company Annual Global Health Care Conference
2015-02-23Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus Biosciences, Inc.
2015-02-23Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors f...
2015-02-23Bristol-Myers Squibb Foundation Awards GRU Cancer Center Three-Year, $1.74M Grant to Address Lung Cancer Among Neediest ...
2015-02-05Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference
2015-01-29U.S. Food and Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir and cobicistat) for the Treatment ...
2015-01-29Celldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdiv...
2015-01-27Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results
2015-01-20Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Be...
2015-01-13Bristol-Myers Squibb and Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with...
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.